COVID Archives - First Washington News

January 23, 2023

COVID vaccine strategy to get an overhaul by FDA : Shots

Licensed vocational nurse Denise Saldana vaccinates Pri DeSilva, associate director of Individual and Corporate Giving, with a fourth Pfizer COVID-19 vaccine booster at the Dr. Kenneth Williams Health Center in Los Angeles, Nov. 1, 2022.

Damian Dovarganes/AP

hide caption

toggle caption

Damian Dovarganes/AP

Updated 10:30 a.m. ET

The Food and Drug Administration is considering a major shift in the nation’s COVID-19 vaccine strategy.

The goal is to simplify vaccination against COVID and perhaps adopt an approach similar that used for the flu vaccine, with annual updates to match whatever strain of the virus is circulating. This is according to a federal official who spoke under the condition of anonymity because they were not authorized to speak publicly.

NPR reported the proposed shift early Monday morning, and later Monday the FDA outlined it publicly in a set of documents released in advance of a meeting Thursday of the agency’s Vaccine and Related Biological Products Advisory Committee (VRBPAC). The committee will vote on the agency’s proposal.

Currently, people who want to be fully vaccinated against COVID have to first get their primary vaccinations — two shots of the original vaccine spaced weeks apart. That’s followed at least two months later by a booster, currently the bivalent shot that’s tailored to protect against omicron.

Under the new approach, most people would be advised to simply get whatever the latest version of the vaccine is annually each fall like the flu vaccine. They wouldn’t have to worry about how many shots they’ve already gotten and which one they got when. Those who still need to receive two doses initially, such as young children and older people, would use the same formulation for all three shots.

Can you get COVID and the flu at the same time?

Vaccine makers would update the annual shot through a process that would begin each spring to try a match the vaccine as closely as possible to whatever variant will likely be dominant in the coming winter. That’s how the flu vaccine is formulated each year.

“FDA anticipates conducting an assessment of SARS-CoV-2 strains at least annually and to engage VRBPAC in about early June of each year regarding strain selection for the fall season,” the FDA wrote in its briefing document, adding that updated vaccines would be readied for use by September each year.

The agency notes that if a more dangerous COVID variant were to emerge, it might reconsider the vaccine strain at other times of the year on an “as-needed and emergent basis”

Some immunologists and vaccine researchers say simplifying the process along the lines of the flu vaccine is appropriate at this point in the pandemic. However, many questions remain about emerging booster strategy.

“As far as the tools that we have right now, I think it just makes the most sense to plan to update each year as close as we can to the currently circulating variant,” says Deepta Bhattacharya, an immunologist at the University of Arizona. “So I think all the things the FDA is considering make a lot of sense.”

Questions about efficacy of updated shots

There’s an intense debate about the wisdom of updating the COVID vaccines regularly to try to match new variants. Some researchers question whether that really makes the vaccines more effective. They also argue the low demand for the latest booster shows the public has little appetite for continued boosting with the vaccines, even if they’ve been updated with new strains.

Is it time for a reality check on rapid COVID tests?

“The public is voting with their arms if you will and said, ‘No. I’m not going to get this. This doesn’t make sense to us,'” says Dr. Gregory Poland, a vaccine researcher at the Mayo Clinic.

While endorsing continued boosters for those at high risk, such as the elderly, some question whether the current bivalent vaccines updated to target omicron have enhanced protection compared to the original vaccines. Most people are still well-protected against severe disease by the immunity they already have, they say.

“We have no solid data about the performance of the bivalent boosters,” says John Moore, an immunologist at Weill Cornell Medical College. “The hard evidence is lacking, and the evidence that is out there is at the very least inconclusive and to me trends towards saying the bivalent boosters were little if no better.”

Moore and others argue the virus is changing so fast that it’s pointless to constantly try to match the vaccines to the latest variants.

“We shouldn’t really be chasing these variants, which are evanescent and are often gone by the time you’ve created the vaccine,” says Dr. Paul Offit of the University of Pennsylvania, one of the FDA’s advisers.

Offit and others also question whether everyone will necessarily need to be boosted regularly, or just those at high risk, like the elderly.

Arguments for alternate vaccine strategies

Critics of the FDA’s proposed new strategy argue it would be better to invest in developing better vaccines that might be more appealing to people, and in campaigns to get more people vaccinated. Better vaccines could include those that could keep people from catching the virus in the first place not just from getting seriously ill — such as a nasal spray vaccine. Or perhaps vaccines that provide longer protection or are administered in pill form, to make them more acceptable to the needle-averse.

“Particularly now when Congress is not allocating new funds for COVID response, we have to be especially judicious in how we spend our money and what would be most cost-effective,” says Dr. Celine Gounder, a senior fellow at the Kaiser Family Foundation. “It’s unclear whether updating the booster formulations and repeatedly boosting people is the most effective approach to controlling COVID at this stage.”

Another concern some researchers have is that the FDA continues to rely on antibody levels to test vaccine efficacy.

“I think we need to raise the bar and require more evidence of clinical efficacy,” says Dr. Eric Rubin, a professor of immunology and infectious diseases at Harvard who is also a member of the advisory committee. For instance, Rubin says the FDA should require proof the updated vaccines are actually reducing the risk of getting infected, getting sick, hospitalized and dying.

Others say updating the vaccines make sense to make sure people are as well-protected as possible while researchers continue to try to develop new vaccines.

“Even if you don’t have a booster that matches 100{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} what’s circulating, you will have a booster that matches 75{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} to 80{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} to 90{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of what’s circulating,” says David Martinez, an immunologist at the University of North Carolina, Chapel Hill. “And that will be good enough. I would probably benefit most people.”

FDA looks ahead to endemic COVID

Some researchers think it’s too soon to rely on annual boosters. COVID hasn’t quite settled into a seasonal pattern like the flu, they note, and the SARS-CoV2 virus is changing more quickly than the flu virus. So people may need to be boosted more frequently, especially since protection against severe disease may only last about four to six months, they say.

“We’re going to be reaching that pretty soon with the early adopters of the bivalent boosters, like myself,” says Dr. Peter Hotez, a vaccine researcher at the Baylor College of Medicine. “I don’t know if an annual strategy is going to cut it.”

The FDA’s plan comes as COVID appears to be moving towards becoming an endemic disease. That doesn’t mean it’s going away or it’s not a threat anymore. The disease will continue to be a threat for the foreseeable future, making many people sick and even potentially killing hundreds a day, making it a major public health problem and a leading cause of death, health experts say.

But unless some more dangerous version of the virus suddenly emerges, the world might finally be settling into a more predictable co-existence with the virus. The federal official NPR spoke to says the goal of the new vaccine strategy is to make the vaccines, which are the major weapon for protecting ourselves, simpler and hopefully therefore more appealing. The latest boosters have found very few takers.

The thinking is that at this point in the pandemic the overwhelming majority of people have a significant levels of immunity, either from having gotten vaccinated and boosted, or infected one of more times, or both. And while that immunity appears to protect most people from severe disease, that protection does appear to fade with time.

The FDA is also considering making the shots interchangeable. That way people wouldn’t have to worry which brand they’re getting. Again, the change is aimed at making COVID shots more like the flu shots. People don’t typically worry about the brand of the flu vaccine they receive.

The vaccine would still be administered at different doses for different ages. And very young children and older people would still get two shots each year, much like the flu vaccine.

If the FDA advisory committee endorses the approach Thursday, the FDA would work with the vaccine companies and Centers for Disease Control and Prevention to finalize the details. And the FDA advisers would meet again in the spring to pick the specific strain or strains of the virus the new shots should target.

January 7, 2023

Updates to know about latest COVID symptoms, infections

The newest COVID-19 variant is so contagious that even people who’ve avoided it so far are getting infected and the 80{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of Americans who’ve already been infected are likely to catch it again, experts say.

Essentially, everyone in the country is at risk for infection now, even if they’re super careful, up to date on vaccines or have caught it before, said Paula Cannon, a virologist at the University of Southern California.

“It’s crazy infectious,” said Cannon, who is recovering from her first case of COVID-19, caught when she was vacationing over the holidays in her native Britain.

“All the things that have protected you for the past couple of years, I don’t think are going to protect you against this new crop of variants,” she said.

The number of severe infections and deaths remains relatively low, despite the high level of infections, she said, thanks to vaccinations – and probably – previous infections. But the lack of universal masking means that even people like her, who do mask, are vulnerable.

A look at the state of the COVID-19 pandemic, according to data from the CDC.

The latest variant, called XBB.1.5, grew exponentially over the month of December, from about 1{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of cases nationwide to 40{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} as of Dec. 31, according to data from the Centers for Disease Control and Prevention. The variant is likely behind the vast majority of cases in New York and New England.

Its growth is probably due to XBB.1.5’s characteristics – it appears to bind even more tightly to receptors in the human body than its predecessors – as well as human behavior, such as traveling and not masking.

It’s a good idea to do what you can to avoid getting infected, said Dr. Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System and a clinical epidemiologist at Washington University in St. Louis.

It’s still early and there are a lot of unknowns about XBB.1.5, he said. Every infection makes someone vulnerable to a bad course of the disease and to the lingering, miserable symptoms of long COVID, Al-Aly’s research shows.

“Reinfection buys you additional risk,” he said.

As the United States enters the fourth year of COVID-19, we’re providing an update on the state of the pandemic. Here’s a preview of what you’ll learn in this article:

What to know about XBB.1.5 symptoms and how long they last

COVID-19 symptoms typically last around five to seven days and can include fever, sore throat, muscle aches, exhaustion, nausea, cough and sinus congestion, among other problems.

Symptoms with XBB.1.5 are the same as with earlier variants and can range from almost nothing to shortness of breath and low oxygen levels that require emergency medical attention.

Early in the pandemic, COVID-19 often cost people their sense of taste and smell, at least temporarily, but that symptom seems less common, possibly because of vaccination or previous infection rather than a change in the virus, said Dr. Peter Hotez, an infectious disease specialist and co-director of the Center for Vaccine Development at Texas Children’s Hospital.

How long does COVID last? How long are you contagious?

It takes anywhere from two to 14 days for exposure to lead to symptoms and a positive test.

People with COVID-19 are contagious as long as they remain positive on a rapid test, typically for about 10 days, but often longer.

The CDC recommends people isolate for at least five days and wear an N95 or similarly protective mask for at least 10 days when around others. Day One is considered the first full day after symptoms start.

A PCR test, which is considered the gold standard for diagnosing COVID-19, can remain positive for months because it detects viral fragments as well as the whole, infectious virus. To confirm the end of the contagious period, experts instead recommend a negative rapid test after 10 days or two within 48 hours if sooner.

Can you get COVID more than once?

Yes. While a previous infection provides some protection, that fades over time and as the virus evolves into different variants.

Some people who had a mild case with a first infection get hit harder the second or third time, while others might suffer less.

“Even if you’ve had it before, that doesn’t mean your next bout is going to be the same,” Cannon said. There are lots of factors at play in determining the seriousness of an infection, she said, including prior immunity, the nature of the variant and how long it’s been since your last infection or vaccination.

It’s possible that her recent infection was much milder than her husband’s, for instance, because she had caught a head cold a few days earlier, while her husband hadn’t. A respiratory virus can put the immune system on high alert and might have provided some protection when she was exposed to COVID-19.

“It’s part of the bigger dance between our bodies and our immune system,” Cannon said.

How to avoid infection

The methods for avoiding infection haven’t changed, though it can be hard to stick with them when no one else is: Get vaccinated, wear a mask and avoid crowded spaces.

First is getting vaccinated. This will protect against severe infection as well as reduce the risk of passing the virus to others, said Hotez, also dean of the National School of Tropical Medicine at Baylor College of Medicine.

The newer boosters, which take aim at both the original virus and the BA.4/BA.5 variants common this summer, are more protective against XBB.1.5 than earlier boosters. People who are up to date on their COVID-19 shots probably don’t shed as much virus for as long, so they’re also less likely to pass it on, he added.

Past infection provides some protection against severe disease, but that protection is “highly unreliable,” Hotez said.

Second is wearing a mask. Good quality, well-fitting masks, like an N95 or KN95 can reduce the risk of infection.

Cannon said people sometimes get annoyed at her mask-wearing “because it’s like I’m reminding them that (COVID) is still a problem.” But she doesn’t want to accidentally pass COVID on to someone who might be more vulnerable to the virus.

Third is avoiding crowded indoor spaces. You’re less likely to get infected in large indoor spaces with high ceilings and lots of ventilation than in cramped, airless ones.

What to do if you get sick

It’s a good idea to have a plan ready in case you get sick, Cannon said. She suggests every plan include:

How to isolate from others in your household

The contact number for a health care provider who can prescribe an antiviral

Equipment such as rapid coronavirus tests, extra masks, a thermometer and a pulse oximeter to make sure the patient’s blood oxygen level doesn’t drop below the low 90s

Every U.S. household is eligible for four free coronavirus tests from the government that can be ordered from this link: covid.gov/tests.

For someone over 60 or with medical conditions like obesity that raise the risk for serious disease, the first step after a positive test should be a call to the doctor to get the antiviral Paxlovid, she and others said. The government has pre-bought millions of doses, so they are available for free.

Some doctors are hesitant to provide the antiviral because people may need to stop taking common medications during the five-day treatment course, but it’s essential for people at high risk for serious disease, Hotez said. “Any senior going on Paxlovid is not dying,” he said.

“We can’t stop people getting infected,” Cannon added, “but we absolutely can stop people from being seriously ill. Gosh, why wouldn’t you take it?”

Why it’s better not to get infected

Every COVID-19 infection increases your risk for serious disease and for long COVID, which brings sometimes debilitating symptoms that can linger for a year or more.

Older adults are more vulnerable, Al-Aly said, “but it doesn’t mean younger people are totally shielded.” Long COVID, too, can strike people at any age from childhood through to the 101-year-old recently treated at his hospital, he said.

Vaccination reduces the risk of long COVID by 15{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} to 30{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, according to a study he recently published. Another study he is working on shows Paxlovid reduces the risk by 26{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

Cannon’s daughter works in a long COVID clinic and regularly sees patients who are in their 20s or 30s, “healthy people who didn’t even have a particularly bad bout of COVID who now have a massively debilitating set of symptoms.”

All six experts interviewed by USA TODAY this week dismissed the idea that there is somehow an upside to getting infected: Vaccination provides better protection against future infection without the risk.

“I’d be happy if I never got any virus again,” Cannon said. “And I say this as a professional virologist.”

Could we be nearing the end of COVID?

COVID-19 has been perhaps the most successful virus in all of human history, Cannon said, infecting billions of people across the planet.

While she worries about how it might continue to evolve, she hopes it’s a good sign that for the last year, all the variants have been descendants of omicron.

Before that, the original virus, alpha, beta and delta had been “radically” different from each other.

“The virus is now in this committed lineage,” Cannon said, which might mean it won’t evolve away from the protection against serious disease that nearly everyone now has from vaccinations and previous infections.

Contact Karen Weintraub at kweintraub@usatoday.com.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Posted on December 25, 2022
Tesla Stock Vs. BYD Stock: Tesla Shanghai Suspends Production As Covid Wave Hits BYD

Tesla (TSLA) and BYD Co. (BYDDF) are both fast-growing EV giants. A lot of attention falls on startups such as Rivian Automotive (RIVN), Lucid (LCID), Nio (NIO), Xpeng (XPEV) and Li Auto (LI), as well as traditional automakers pushing into EVs, such as General Motors (GM) and Ford Motor (F). But Tesla and BYD are setting the pace.

X

Tesla Shanghai suspended production as of Dec. 24 after curbing output back on Dec. 12 due to swelling inventories, even with big year-end discounts. Tesla also is offering various year-end incentives in Europe and the U.S.

BYD sales have been booming, but the China EV giant said Dec. 22 that Covid infections among factory workers is curbing its output.

Including plug-in hybrids, BYD has surged past Tesla sales. It’s closing the gap on BEVs, with sales soaring yet again in November. BYD continues to open new plants, with plans for its first factories outside China, including Thailand, Brazil and, soon, Europe.

Tesla stock has plunged in recent weeks on signs of weak demand as well as concerns about Elon Musk’s tweets on Tesla’s brand.

BYD stock is off bear-market lows, bouncing as China eased Covid rules. But it’s retreating now on resulting coronavirus wave.

Let’s take a look at Tesla vs. BYD — and Tesla stock vs. BYD stock.

Tesla Vs. BYD Sales

Tesla reported Q3 deliveries of 343,830 cars, up 42{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. a year earlier and above Q1’s record 310,048. But that was below analysts’ estimates of above 360,000. Tesla produced 365,923 vehicles in the latest quarter, more than 22,000 above deliveries.

Tesla delivered 325,158 Model 3 and Model Y vehicles in Q3, along with 18,672 Model S and Model X luxury EVs.

BYD sold 230,427 all-electric and plug-in hybrid vehicles in November, up 153{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. a year earlier and 5.8{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. October. That includes 229,942 personal vehicles and 485 commercial units. Of those personal vehicles, some 113,915 were fully electric, or battery electric vehicles (BEVs), up 147{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. November 2021. Plug-in hybrids shot up 164{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} to 116,027.

Over the past three months, BYD has sold 649,502 BEVs and PHEVs, including 312,013 BEVs.

BYD’s 90{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}-owned Denza unit reported sales for the first time, with 350 Denza D9 minivans sold in October and 3,481 in November. The D9, which comes in BEV and PHEV formats, starts around $50,000. Mercedes-Benz owns 10{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of Denza.

Tesla Expansion, Demand

Tesla opened its plants near Berlin, Germany, and Austin, Texas in March and April, respectively. Model Y production has ramped up slowly at those sites, but is improving.

Recent upgrades to the Tesla Shanghai facility significantly boosted production capacity. But Tesla China demand is struggling to keep up with increased output.

Tesla sold a record 100,291 China-made EVs in November. That includes exports.

Tesla cut actual Model 3 and Model Y prices in China on Oct. 24 by as much as 9{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

Tesla is now offering a 6,000 yuan ($860) discount on inventory cars in China, on top of an existing 4,000 yuan insurance subsidy. Along with other incentives, Tesla China is offering over 21,000 yuan in incentives, with even more in Shanghai and Shenzhen.

All that’s before government subsidies of 11,088 yuan. Those government subsidies expire Dec. 31. So buyers will be paying more for many Tesla vehicles, and other EVs, in 2023. However, Tesla China sales are still weakening in December, according to China vehicle registration data.

Tesla Shanghai reportedly slowed production on Dec. 12 and halted output on Dec. 24, amid rising inventories. Workers are set to return on Jan. 1. Tesla had denied reports that it would slower or suspend Shanghai output.

Tesla exported more Shanghai vehicles in Q4 to ease local demand concerns. But that, along with increased Tesla Berlin production, is reducing European backlogs.

Germany will reduce EV subsidies as of Jan. 1. Norway is ending subsidies. Sweden has just ended subsidies with U.K. subsidies winding down soon.

Even with some pull-forward demand due to the expiring subsidies, Tesla is now offering 10,000 free Supercharging kilometers in Europe for taking delivery before year-end. It’s also offering some Model Y discounts in the U.K.

All of that suggests weaker European demand in 2023.

Over in the U.S., many Tesla vehicles will be eligible for new U.S., tax credits of up to $7,500 as of Jan. 1, subject to a variety of conditions.

That’s spurring many would-be buyers to delay purchases or delivery until Jan. 1. In December, Tesla offered $3,750 off and 10,000 free Supercharger miles for people taking U.S. delivery of a Model 3 or Model Y before year-end. On Dec. 21, Tesla upped that discount to $7,500.

Meanwhile, Tesla reportedly will soon announce plans to build its next EV plant in northeastern Mexico. That would offer a relatively low-cost site while still being close to the U.S. market. It’s unclear which vehicles might be produced at the plant, which presumably would not be operational until 2024 at the earliest.

BYD Expansion

BYD also is adding significant EV and battery capacity.

The auto giant’s NEV deliveries should more than triple to 1.88 million in 2022, a BYD exec said Dec. 22. That’s slightly below its prior hopes for 1.9 million, due to a recent Covid outbreak among factory workers. That’s curbing daily production by at least 2,000 vehicles.

There’s concern that Covid waves, which will likely continue beyond the Lunar New Year in late January, will hinder production, supply chains and demand in China broadly.

BYD Chairman Wang Chuanfu has set a 2023 delivery goal of 4 million.

Tesla, targeting the luxury and affordable luxury markets, has far higher selling prices than BYD. The majority of BYD’s EVs and hybrids sell for $15,000-$34,000, though a growing number top $40,000.

The China EV giant also plans to move upscale significantly. The Denza unit moves BYD into the affordable luxury space. A Denza SUV should join the D9 minivan in early 2023.

BYD said it would raise China prices as of Jan. 1, citing battery material costs, even though that’s when government subsidies end.

BYD also plans to launch two more brands in 2023.

The first, called Yangwang, which means “looking up,” will target the luxury market for 800,000 yuan ($110,300) or more, starting with an off-road SUV.

BYD also will launch a personalized brand next year, with few details given.

Economy, S&P 500 Face Hard Landing — Unless The Fed Does This

BYD Vs. Tesla: Tesla Electric Vehicles

Tesla mass produces four electric vehicles: the luxury Model S sedan and Model X SUV as well as the Model 3 sedan and Model Y crossover. The vast majority are the Model 3 and Model Y, with the Model S and X largely limited to North America for now.

On Dec. 1, the first Tesla Semi deliveries took place, with PepsiCo (PEP) the first customer. The Tesla Semi was first unveiled in 2017. But the Tesla Semi will not use 4680 batteries, raising questions about costs. It’s also unclear if the Semi will be produced in volume or in token amounts.

The Roadster and Cybertruck also have been pushed back multiple times. Musk says the Cybertruck is on track for “early” production mid-2023, with a Reuters report saying mass production will start at the end of 2023.

Put prices and specs will likely be different from the initial Cybertruck claims back in 2019, Musk says.

The Cybertruck likely will largely serve the U.S. market. So Tesla may not have a new passenger EV for most of the world until 2024 or later.

Tesla may be updating its Model 3 sedan at some point in 2023, with the goal of lowering production costs and improving its appeal. The “Highland” redesign reportedly will include some changes to the interior and exterior, as well as possible change to the powertrain.

Model 3 sales have flattened out, in part due to people opting for the Model Y crossover but also due to competition from the BYD Seal, Nio ET5 and many more.

Musk also recently stated that Tesla is working on a much-cheaper EV, signaling a possible return to a long-touted goal of a $25,000 vehicle. However, he gave no timeline. Even now, such a model would run into dozens of existing rivals, mostly from Chinese EV makers such as BYD.

BYD Vs. Tesla: BYD EVs Big And Small

BYD has a slew of models, some with electric and hybrid versions. The automaker is rolling out several new EV-only and hybrid-only models in the next several months.

The Seal sedan is BYD’s first clear head-to-head competition vs. Tesla. The BYD Seal has roughly equal dimensions and range to a Model 3 — and is far cheaper. The Seal starts at 212,800 RMB ($29,617) vs. 265,900 RMB ($37,007) for a made-in-China Model 3, even after Tesla’s price cuts.

BYD started Seal deliveries in late August, with deliveries reaching 11,267 in October. Production is set to keep ramping up and will reach many overseas markets in 2023.

BYD unveiled Frigate 07, a mid-size SUV that’s the second model in the Warship line of plug-in hybrids. The Destroyer PHEV sedan launched this spring.

BYD also is one of the biggest makers of electric buses, with plants in the U.S. and many other countries besides China. BYD also makes EV delivery trucks, big rigs, garbage trucks and more.

BYD makes buses, big rigs and other heavy vehicles for the U.S. market at its Lancaster, Calif., plant.

The Best EV Stocks To Buy And Watch

Tesla Stock Vs. BYD Stock: EV Markets

Tesla is a global EV giant, with major sales in North America, Europe and China. It has notable business in Korea, Japan, Australia and some other Asian markets. It has four plants, starting with Fremont, Calif., and Shanghai, joined by the Austin, Texas, and Berlin-area plants. Tesla already exports to Europe, mostly from Shanghai.

Tesla is launching in Thailand, but it’s unclear when deliveries will start.

As the Berlin plant ramps up, the Shanghai plant will export fewer Model Ys to Europe, though Model 3 shipments will likely continue.

While Tesla capacity is soaring, it has no major new markets to enter or new passenger EVs in the near future.

The U.S. recently approved new EV tax credits. Tesla, no longer eligible under the old program, should be a winner. Income and vehicle price caps will limit some Tesla vehicles’ and buyers’ eligibility. A requirement for a high and rising share of battery materials and components from North America also could complicate matters.

But, if nothing else, the new rules — which mandate assembly in North America — cut off tax credits to many Tesla rivals.

BYD’s auto plants are in China, with virtually all its sales there, but those are both changing.

The company has just opened a semi-knocked down assembly plant, in which partially assembled vehicles are imported and finished to get lower import tariffs.

BYD will build a manufacturing plant in Thailand. The export-focused plant should be running in 2024 with an annual production capacity of 150,000 vehicles.

BYD will build three plants in northeastern Brazil, including one for passenger vehicles. The plants will begin operation in 2024-2025.

A top BYD executive said recently that the company is planning on an EU factory, perhaps two.

Exports reached 12,318 in November, up from 9,529 in October and 4,026 in July. They should keep surging in the next several months.

BYD has started Atto 3 deliveries in New Zealand, Australia and Singapore. The Atto 3 is the Yuan Plus’ name for most overseas markets. Several other Asian countries will follow in the next few weeks and months, including Thailand, Malaysia, India and Japan.

BYD has started deliveries across much of Europe, expanding from just the Norway market. BYD set European pricing well above the sticker price for those vehicles in China, suggesting the automaker is looking to establish itself as a premium or near-premium brand on the Continent.

BYD in early October agreed to sell more than 100,000 EVs to German car rental giant SIXT over six years. That follows Tesla and GM EV deals with Hertz (HTZ). SIXT says it will order several thousand BYD EVs to start.

The EV giant will enter Japan with the Atto 3 in early 2023, the Dolphin/Atto 2 midyear and Seal/Atto 4 in late 2023.

BYD is increasing its sales in Latin America, ramping up in Brazil in particular. The automaker said in late November that it will enter Mexico in 2023. It’s also planning to enter Chile, a major lithium producer.

America isn’t officially in BYD’s sights in terms of personal EVs. Tariffs on China-made autos make exports to the U.S. cost prohibitive. BYD does make some EV buses here, with a lot of extra space at its Lancaster, Calif., site outside Los Angeles.

BYD is mulling building a battery plant in the U.S., but not currently making EVs here.

EV ‘Freak-Out’ Moment Looms Over Lithium, Rare Earths

Tesla Vs. BYD Batteries

Tesla doesn’t mass produce battery cells. The Sparks, Nevada, gigafactory is a joint venture with Panasonic, which makes the cells. In China and increasingly in the U.S., Tesla buys off-the-shelf batteries from CATL.

It’s increasingly shifting to lithium iron phosphate batteries. LFPs have some cost advantages, which have grown because they don’t require any cobalt or nickel, unlike lithium-ion batteries.

Tesla has long led in getting more out of its batteries, though the high-end Lucid Air has higher battery efficiency than Tesla.

Tesla is developing its own 4680 battery cells in a pilot program. The 4680 batteries don’t involve new chemistry. The larger form factor offers the potential for cost savings, but technical challenges remain.

BYD batteries, by contrast, are truly in house. The BYD Blade batteries, a specialized LFP battery, are seen as among the safest available for EVs.

BYD also is working on sodium-ion batteries, which offer lower range but would be much cheaper. They could be useful for small-range vehicles or for storage, where energy density is less of an issue.

BYD is now supplying Blade batteries to Tesla Berlin. It’s a major validation, as BYD aims to be a major battery supplier to third-party automakers.

The made-in-China Ford Mustang Mach-E uses BYD batteries.

Toyota (TM) will use BYD batteries and motors in an upcoming small EV for the Chinese market, the bZ3. BYD may be actively involved in Toyota’s wider EV push in the coming years.

BYD and Tesla are on the forefront of automakers trying to lock up supplies of lithium and other key battery raw materials.

Musk has discussed Tesla getting involved in lithium mining, but hasn’t done so. Tesla has proposed a lithium processing plant in Texas.

BYD is involved in several lithium mining projects already.

Time The Market With IBD’s ETF Market Strategy

Tesla Beyond EVs

Tesla and BYD are more than just EV makers.

Tesla has solar and battery storage businesses, but both are a small part of total revenue.

Tesla also generates revenue via its Supercharger network. It’s starting to open its Supercharger network to non-Tesla vehicles in parts of Europe, where third-party charging stations are common. In the U.S., the Supercharger network is still a big moat for Tesla, but the automaker may open at least some stations to attract new subsidies.

Tesla CEO Elon Musk tweeted on Thanksgiving that Full Self-Driving Beta is now available to any FSD owners in North America who request it.

That could allow Tesla to recognize more deferred revenue from FSD. Tesla’s self-driving efforts have been a key revenue driver and brand builder.

But Full Self-Driving is not full self-driving. Even FSD Beta is a Level 2 driver-assist system, while many U.S. and China rivals are rolling out Level 4 robotaxi services in select urban areas.

The Justice Department reportedly is conducting a criminal probe of Tesla’s self-driving claims. The SEC has a civil probe of Tesla’s claims. The California DMV in July accused the EV giant of misleading customers about Autopilot and FSD.

The National Highway Traffic Safety Administration has expanded an Autopilot probe multiple times, looking into crashes into stationary emergency vehicles, “phantom braking,” in-cabin cameras and even how Tesla assembles reports that claim to show Autopilot’s safety benefits.

Still, Tesla raised the price of FSD in North America to $15,000 from $12,000 in early September.

An Optimus robot prototype was unveiled at Tesla AI Day on Sept. 30, with limited mobility. Musk said Optimus should go on sale in 3-5 years for less than $20,000. Most experts say general purpose humanoid robots are decades away.

BYD Semiconductor, Solar And More

BYD makes its own chips, which has helped it rapidly expand over the past year while the industry had to idle production.

The company also has solar and energy storage businesses, as well as a variety of other operations.

BYD said in mid-December that it had deployed 6.5 gigawatts’ worth of battery storage so far in 2022. That’s likely at least equal to Tesla, which deployed 4.08 GWh of battery storage in Q1-Q3, with just over half of that in Q3.

BYD’s massive battery plant expansion is driving its own EV growth and third-party EV sales, but will help the storage business boom next year.

BYD’s chairman has said driver-assist systems will be introduced in 2023. But BYD has various autonomous driving initiatives, with Baidu (BIDU), Nvidia (NVDA), China’s Momenta. BYD says it will use chips from Horizon Robotics in some 2023 models and has a stake in Lidar supplier RoboSense. BYD reportedly is working on in-house Lidar and self-driving chips as well.

Five Best Chinese Stocks To Watch Now

Tesla Stock Vs. BYD Fundamentals

Tesla earnings more than tripled to $2.26 a share in 2021, vs. 75 cents in 2020 and just 1 cent in 2019.

Tesla earnings rose 69{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in Q3 while revenue grew 56{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, but the top-line gain fell short.

Tesla’s gross margin was 25.1{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, with an automotive margin of 27.9{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, both roughly flat vs. Q2 but down from a year earlier. Tesla excludes R&D costs and service center overhead from those figures. Overall gross margin including R&D costs was 21.7{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

With production set to surge in Q4, Tesla said it will make more vehicles than it deliveries for a second straight quarter. It says that’s intended to ease logistic challenges and costs.

BYD earnings declined in 2021. Capital spending last year exceeded capex from 2018-20 combined, with huge outlays for new auto, battery and chip plants. EV and PHEV production capacity has surged and continues to increase. With sales skyrocketing, and BYD’s selling prices rising, that is spurring massive revenue and profit gains this year.

On Oct. 28, BYD reported third-quarter net income jumped 350{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. a year earlier in local currency terms, with revenue up 116{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}. Adjusted earnings spiked 923{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

BYD’s gross margin was 18.96{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in Q3, up from 14.39{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in Q2 and 13.33{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} a year earlier. Automotive gross margin was 22.77{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. 17.82{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in Q2 and 17.31{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} vs. a year earlier.

With sales and ASPs continuing to ramp up in Q4, BYD profits and gross margins are likely to improve vs. Q3.

IBD’s 100 Best ESG Companies For 2022

Tesla Stock Vs. BYD Stock Technicals

Tesla stock is down 65{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} this year as of Dec. 23, according to MarketSmith analysis. BYD stock is off 28{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

TSLA stock hit a record 414.46 in November 2021.

Musk’s chaotic reign of Twitter has raised concerns for Tesla investors. He’s driven away advertisers with his tweets and policies, with the latter often in flux Musk’s rising negatives could hurt the Tesla brand in the U.S. The high year-end U.S. discounts may reflect, in part, Tesla brand damage.

Tesla CEO Elon Musk says he’ll step down as Twitter’s chief when he finds a new CEO, following a user poll supporting the idea. It’s something many high-profile TSLA bulls have urged. The poll closed with a majority voting “yes.”

But shares have kept tumbling in heavy volume, amid ongoing concerns about Tesla demand. TSLA stock is at its worst levels since September 2020.

Late on Dec. 22, Musk pledged not to sell more Tesla stock until at least 2024. Musk has sold $39 billion in TSLA stock since the November 2021 peak, including $3.5 billion in the three days ended Dec. 14.

BYD hit record highs in June, but then tumbled. Berkshire has sold small slices of its H-shares in BYD in six moves, starting in late August. The latest was disclosed on Dec. 13.

Berkshire still owns around 7{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of BYD, based on all share classes.

BYD stock hit a fresh bear market low on Nov. 25. But shares bounced with other China EV makers on Covid easing hopes, retaking the long-sliding 50-day line. Shares retreated below the 50-day line on Dec. 23, with a long distance to the 200-day.

Tesla Stock Market Cap

In terms of market cap, Tesla stock vs. BYD stock is no contest. Tesla is worth $388.9 billion, but well off its peak valuation above $1 trillion. That’s still far above BYD’s $66.8 billion.

An S&P 500 giant, Tesla stock has an array of institutional sponsorship, including many IBD-style mutual funds and other A+ funds. TSLA stock remains a major holding across Ark Invest’s ETFs.

BYD stock has far-less big sponsorship, though Buffett’s Berkshire has been a notable investor for years. Cathie Wood’s Ark also owns a small stake. Very few stocks can boast both Buffett and Wood as investors.

BYD stock is listed in Hong Kong and Shenzhen, and only trades over the counter in the U.S. That also means the BYDDF stock chart shows a lot of minigaps.

Tesla Stock Vs. BYD Stock

In many ways BYD is what Tesla claims or aspires to be. BYD makes its own batteries and chips, as well as many other key parts. It’s selling its batteries to other automakers, including Tesla itself. Musk has long touted a goal of a $25,000 Tesla. BYD already sells many EVs at or below $25,000, and at a profit. Musk has mulled getting involved in lithium mining. BYD already is.

BYD’s EV and PHEV unit sales have raced past Tesla’s unit sales, with the automaker accelerating production and moving toward more-upscale offerings. For now, Tesla sells more far more pure electrics than BYD and at higher price points. But the BEV gap is rapidly narrowing, while BYD’s average prices are trending up. Both are reporting booming earnings.

BYD has expanded in several big markets, with several more in the next few months.

Both EV giants are delivering far more electrified vehicles than rivals.

Tesla stock and BYD stock were among the biggest EV winners in 2021. Both are down sharply in 2022, especially Tesla. Both EV giants need serious repair.

So, Tesla stock vs. BYD stock? Investors should keep their eyes on them.

Please follow Ed Carson on Twitter at @IBD_ECarson for stock market updates and more.

YOU MAY ALSO LIKE:

Why This IBD Tool Simplifies The Search For Top Stocks

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today

Tesla Stock On Track For Worst Year Ever: Four Big Headwinds

Cathie Wood Has Bet Big On These 10 Stocks; Here’s How They’re Performing

Futures: Inflation Report Data; Elon Musk Pledge Lifts Tesla

Posted on November 8, 2022
Nio production hit by China’s COVID restrictions

Chinese electrical-car or truck maker Nio has fallen powering on both equally creating and offering 1000’s of autos more than the previous thirty day period as COVID-19 constraints disrupted output at its two factories, in accordance to individuals acquainted with the make a difference.

Manufacturing at the plants in Hefei, Anhui province, have also been impacted by delays in the source of some elements, the people today mentioned, asking not to be recognized due to the fact the particulars are private.

U.S.-mentioned Nio tried to run so-called shut-loop programs at the factories — which call for staff to remain on site, making it possible for generation to continue on even if a lockdown is in area — but individuals efforts unsuccessful thanks to a lack of components, a single of the people mentioned.

The disruptions have intended a decline of close to 7,000 electrical automobiles in production, that means deliveries have dropped by about 5,000, a person of the individuals said.

Nio on Tuesday described 10,059 deliveries for October, down 8 p.c on September’s quantities. Manufacturing at both factories has now partly resumed, the people today reported.

A consultant from Nio declined to comment. Chinese publication 36kr previously described the COVID curbs had impacted Nio’s generation.

In line with China’s COVID Zero plan, Hefei, in central China, shut quite a few indoor services, such as cinemas, gyms, web cafes and bars, when virus circumstances conditions emerged.

In-particular person classes at middle, major educational institutions and tutoring establishments have been halted and colleges are also matter to shut-loop programs.

Nio’s practical experience demonstrates how China’s zero-tolerance technique to the pandemic is upending business enterprise and the world’s second-biggest economy, with manufacturing unit functions and offer chains impacted. When shut loops enable firms to stay operational for the duration of lockdowns, they consider a toll on employees, whose movements are seriously constrained, with some even demanded to rest on manufacturing unit flooring.

Personnel are departing the world’s largest Apple iphone plant, in Zhengzhou, central China, just after unexpectedly enacted COVID constraints left lots of of the 200,000 employees grappling with insufficient dwelling situations.

Tesla successfully made use of a closed loop to resume output for the duration of Shanghai’s months-prolonged lockdown before this calendar year.

Shanghai-centered Nio has two factories in Anhui province. The to start with, co-operated with Anhui Jianghuai Vehicle Team, can make as several as 240,000 cars a calendar year, when the other, which started mass production before this year, is just ramping up to full capacity, producing the company’s most up-to-date ET5 model sedan.

Posted on October 1, 2022
How the CDC’s communication failures during Covid tarnished the agency

In the early times of Covid, staffers at the Facilities for Condition Manage and Prevention sought to give Americans steerage about preserving some semblance of normalcy through a at the time-in-a-century pandemic that experienced upended each day life.

One advice? Engage in basketball with your good friends — on line.

There was a single massive problem: The nation’s prime general public overall health industry experts unsuccessful to consult with their very colleagues who’d be dependable for communicating this tips to the community.

“We have to have a seat at the desk sooner, so we can elevate our hand and say, ‘Hey fellas, I’m sorry, but enjoying basketball nearly with your mates is almost certainly not a wonderful advice,’” a CDC staffer explained to NBC Information before incorporating: “That’s rather silly.”

An additional staffer echoed the frustration. “There ended up a quantity of folks inside of the company that had been sometimes perplexed at regardless of whether what we were recommending was definitely useful.”

Communication failures like that, together with considerably much more consequential mistakes, would continue throughout the pandemic, deeply tarnishing the agency — lengthy regarded as the gold normal of general public health and fitness institutions. The blunders have left job researchers and other longtime staff nervous that the wounds just cannot be healed.

All culminated in what would become a sequence of unsettlingly defining times for CDC staff who say the agency was not able to move speedy plenty of for the general public with science solid plenty of to fulfill their possess expectations.

This account is primarily based on interviews with 7 CDC workers who spoke to NBC News about their encounters throughout the pandemic on the issue of anonymity to go over issues freely. All but just one have been with the agency for at the very least 14 several years, and 3 are nearing or have exceeded their third decade of assistance.

Though some staff members say they are optimistic that the company can make improvements to its general public wellness responses, blunders for the duration of the Covid reaction nevertheless haunt those people who have devoted their life to community well being.

“When men and women inquire, ‘where do you work?’ I employed to say that ‘I function at CDC’ with pleasure,” a staffer mentioned. “Now I just convey to individuals that I work in community wellbeing and not exactly in which I work, due to the fact it’s just going to develop into a discussion of our failures.”

“People’s life were being changing based on our conclusions,” reported a senior scientist inside of the company. “The anxiety, the stress and anxiety, the strain …” the man or woman mentioned, trailing off. “If only we could have stopped time.”

“There are heading to be headlines that praise you and headlines that slam you,” the CDC’s director, Dr. Rochelle Walensky informed NBC News. “It was heading to be hard for the agency however it shook out. I can convey to you various periods the place I’ve experienced these major decisions… a lot of evenings I have lost sleep.”

Six of the CDC workers who spoke to NBC News were being both interviewed for or were in any other case intensely included in a very publicized assessment of the agency this year. The assessment was asked for by Walensky and led by Jim Macrae, a longtime formal in the Department of Well being and Human Products and services.

“In our significant moment, our general performance did not reliably satisfy anticipations,” Walensky reported in a statement in August, when the evaluation was finished. Macrae’s report on the agency’s pandemic reaction, printed Sept. 1, echoed the need to have for the CDC to transfer far more promptly and reliably.

Not all workers had been content with the proposed adjustments. “I absolutely have talked to workers who are very distressed by it and really feel extremely concerned,” a senior staffer claimed.

A different was additional blunt: “It’s gonna piss off a great deal of men and women, and men and women are likely to depart.”

But other individuals reported they ended up relieved to see their frustrations outlined in Macrae’s closing report, and in the end, all agreed that the agency have to make drastic alterations in advance of the subsequent community health and fitness unexpected emergency.

Posted on September 23, 2022
Covid Still Kills, but the Demographics of Its Victims Are Shifting

Phillip Reese

As California settles into a 3rd 12 months of pandemic, covid-19 proceeds to pose a major danger of demise. But the variety of people today dying — and the demographics of individuals slipping target — has shifted notably from the to start with two yrs.

Provided the collective immunity men and women have garnered via a mix of mass vaccination and protections crafted from previously infections, Californians total were far less very likely to die from covid in 2022, when the omicron variant dominated, than throughout the first two decades of the pandemic, when other variants were mostly at perform, amplifying a countrywide craze.

Still, each week, the virus is killing hundreds of Californians, hitting most difficult amongst the unvaccinated. The virus remained amongst the state’s main causes of loss of life in July, trailing heart ailment, cancer, stroke, and Alzheimer’s condition but outpacing diabetic issues, accidental loss of life, and a host of other debilitating diseases. In the very first seven months of the 12 months, about 13,500 California inhabitants died of covid, in accordance to preliminary dying certificate details from the point out Division of General public Well being. By comparison, the virus killed about 31,400 persons in 2020 and nearly 44,000 in 2021.

From April 2020 by December 2021, covid killed an ordinary of 3,600 men and women a month, building it the 3rd-major induce of loss of life in the condition cumulatively for that time time period, powering heart condition and most cancers. From December 2020 through February 2021, it briefly overtook heart illness as the top induce of death, having the lives of much more than 38,300 Californians in just three months. Through its most current peak, in January 2022, covid took about 5,900 life.

Covid fell out of the major 10 causes of death for a quick period in the spring only to reenter this summertime as the omicron variant ongoing to mutate. In July, even with additional than 70{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of Californians absolutely vaccinated, covid was the fifth-primary lead to of loss of life, chopping shorter extra than 1,000 life, point out details display.

Evidently vaccinations manufactured a difference. Covid loss of life rates fell in latest months as covid shots and prior bacterial infections afforded a lot of the population substantial protection in opposition to severe sickness, explained Dr. Timothy Brewer, a professor of drugs and epidemiology at UCLA. Brewer stated the omicron variant, even though extra transmissible than previously strains, appears to be a milder model of the virus. Analysis into that issue is ongoing, but preliminary facts suggests omicron is considerably less likely to cause critical illness and demise, in accordance to the Centers for Disorder Management and Prevention, which also notes that the severity of signs or symptoms can be affected by vaccination standing, age, and other well being ailments.

The decline in fatalities was specially striking amongst California’s Latino inhabitants.

In 2020 and 2021, Latino inhabitants accounted for 47{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of covid fatalities in California — about 35,400 fatalities — while they make up 40{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s population. By comparison, Latinos accounted for 34{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of covid deaths from January by way of July 2022, in accordance to state details. That interprets to about 4,600 fatalities.

Conversely, the proportion of covid deaths involving white citizens amplified from 32{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in the 1st two yrs of the pandemic to 44{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in the very first seven months of 2022. That equates to 24,400 deaths involving white inhabitants in 2020-21 and about 6,000 fatalities in the initial seven months of 2022. White folks make up about 35{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s inhabitants.

Scientists issue to numerous elements in the shift. Through the initial two several years of the pandemic, substantial quantities of the staff considered critical, who continued to report to position web pages in human being, have been Latino, when white citizens had been much more possible to be utilized in occupations that permitted them to get the job done from dwelling, U.S. Census Bureau surveys display.

“They just bought uncovered a lot more,” stated Dr. George Rutherford, a professor of epidemiology and biostatistics at the University of California-San Francisco. “They’re executing essential employment and experienced to go away the household and go to do the job.”

An imbalance in distant get the job done remains, census details displays, but right now the massive vast majority of both Latino and white workers in California are reporting to operate in person.

Seciah Aquino, deputy director of the Latino Coalition for a Healthier California, stated efforts to make positive that testing, cure, and vaccinations had been obtainable to underserved communities of coloration also had an impression. And mainly because Latino communities have been hit so really hard for the duration of the pandemic, she reported, quite a few California Latinos are even now putting on masks. “They are nevertheless creating positive that they’re being home if they are unwell,” she mentioned. “They’re continue to abiding by these insurance policies even if the increased narrative is shifting.”

Age is also a essential variable in the demographic shifts, Brewer reported.

Californians age 75 and older produced up 53{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of covid fatalities through July in 2022, up from 46{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in 2020 and 2021. Only about 6{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s people are 75 and older. And white Californians 75 and more mature outnumber Latinos in that age group about 3 to 1.

In the first vaccination rollout, California prioritized seniors, very first responders, and other necessary personnel, and for many months in 2021 older people have been a great deal a lot more most likely to be vaccinated than younger Californians.

“Now, the vaccination charges have caught up fairly a great deal with every person except for young children, men and women less than 18,” Brewer mentioned. “You’re viewing it go again to what we observed just before, which is that age stays the most significant chance factor for demise.”

Far more than 86{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of Californians age 65 and older have done their key covid shot sequence. But the safety afforded by vaccines wanes about time, and because several seniors got their pictures early, sufficient time passed in between their second shot and the omicron wave of early 2022 to go away them vulnerable. About a single-third of Californians 65 and more mature had not been given a booster by early 2022, when the omicron wave peaked, and about 1-quarter still have not obtained a booster.

Geographic shifts in covid prevalence have transpired through the pandemic: Outbreaks strike just one spot though another is spared, and then a different community serves as the epicenter a several months later.

People of the San Francisco-Oakland metro location accounted for 7.8{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s deaths in 2022, by way of early September, up from 5.4{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in 2020-21. The spot is house to about 12{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s citizens. The Sacramento metro area has also accounted for a bigger share of covid fatalities this yr: 6{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in 2022 versus 4.5{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in 2020-21.

At the identical time, Los Angeles-Very long Seashore-Anaheim metro inhabitants designed up 42{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of covid deaths in 2022, down somewhat from 43{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} in 2020-21. The spot is property to about 33{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of the state’s inhabitants. A very similar dip occurred in the nearby Riverside-San Bernardino metro area.

Once again, age could be a issue in the geographic shifts. A bigger proportion of citizens in San Francisco and Sacramento are 75 and more mature than in Los Angeles and Riverside, census facts exhibit.

It is unclear no matter whether this change will final. As the Los Angeles Occasions described, covid deaths grew at a more quickly rate in July in L.A. County than they did in the Bay Area.

The knowledge also shows that vaccination stays a person of the strongest deterrents to dying from covid. From January by means of July, unvaccinated Californians died at about five occasions the amount as vaccinated Californians. But the gap has narrowed. From April by means of December 2021, California’s unvaccinated people died, on common, at all over 10 moments the price of vaccinated Californians.

Brewer explained the hole lessened since the omicron variant was additional possible than earlier variants to “break through” and cause an infection in vaccinated Californians. The omicron variant, while considerably less lethal, also contaminated a lot of much more people today than earlier variants.

This development, also, may perhaps establish shorter-lived: The next era of covid booster pictures are rolling out across the state.

Phillip Reese is a data reporting professional and an assistant professor of journalism at California Point out University-Sacramento.

This tale was manufactured by KHN, which publishes California Healthline, an editorially independent support of the California Overall health Treatment Foundation.

KHN (Kaiser Health Information) is a national newsroom that generates in-depth journalism about well being concerns. Together with Coverage Analysis and Polling, KHN is a single of the 3 key running packages at KFF (Kaiser Household Foundation). KFF is an endowed nonprofit group offering information on wellbeing challenges to the nation.

USE OUR Content

This tale can be republished for cost-free (specifics).

Posts pagination

Page 1 Page 2 … Page 11 Next page